Fig. 5: Slc7a5 is essential for TIL expansion and tumor growth control in mice.

A AT3 cells were injected orthotopically in breast in WT (n = 9) and Slc7a5.TKO (n = 8) C57BL/6 mice. Shown is tumor image. B Tumor size and weight as in A were quantified and presented. C The tumor-bearing mice as in A were sacrificed after 14 days and the lungs were inflated by India ink. The tumor nodules were quantified and presented. D B16F10 cells were injected subcutaneously in WT (n = 4) and Slc7a5.TKO (n = 7) C57BL/6 mice. Shown is tumor image. E Tumor size and weight as in D were quantified and presented. F Spleens were collected from AT3 tumor-bearing WT and Slc7a5.TKO C57BL/6 mice as in A and analyzed by flow cytometry for CD8⁺, CD4⁺ and CD11b⁺ cells. Shown are representative dot plots. G Quantification of indicated immune cells as in (F). H Tumor tissues were collected from AT3 tumor-bearing WT and Slc7a5.TKO C57BL/6 mice as in A and analyzed by flow cytometry for CD8⁺, CD4⁺ and CD11b⁺ cells. Shown are representative dot plots. I Quantification of indicated immune cells as in (H). J Spleens were collected from B16F10 tumor-bearing WT and Slc7a5.TKO C57BL/6 mice as in D and analyzed by flow cytometry for CD8⁺ and CD4⁺ cells. Shown are representative dot plots. K Quantification of indicated immune cells as in (J). L Tumor tissues were collected from B16F10 tumor-bearing WT and Slc7a5.TKO C57BL/6 mice as in D and analyzed by flow cytometry for CD8⁺ and CD4⁺cells. Shown are representative dot plots. M Quantification of indicated immune cells as in (L).